Investment Thesis
CVRx is a pre-profitable medical device company with strong 87.2% gross margins indicating viable products, but is burning $12-13M annually in operating and free cash flows with no clear profitability timeline. While excellent liquidity ($72.3M cash) provides 5-6 years of runway and 10.4% revenue growth shows demand, the combination of negative operating leverage, 2.01x debt/equity ratio, and inability to cover interest from operations presents material downside risk for fundamental investors.
Strengths
- Exceptional gross margin of 87.2% demonstrates strong underlying unit economics and product value
- Substantial cash position of $72.3M relative to company size provides operational runway
- Revenue growth of 10.4% YoY with stabilizing losses (EPS improved 23% YoY) suggests operational efficiency gains
Risks
- Negative operating cash flow (-$12.2M) and free cash flow (-$12.3M) indicate ongoing cash burn from core operations
- High leverage (2.01x debt/equity) combined with negative interest coverage (-12.7x) creates refinancing risk
- Pre-profitable status with $14.8M revenue generating -$12.2M operating loss indicates significant scaling risk before profitability
Key Metrics to Watch
- Path to operating profitability and operating margin trend trajectory
- Quarterly cash burn rate relative to cash reserves and runway estimate
- Revenue growth acceleration and gross margin sustainability as scale increases
Financial Metrics
Revenue
14.8M
Net Income
-13.1M
EPS (Diluted)
$-0.50
Free Cash Flow
-12.3M
Total Assets
99.7M
Cash
72.3M
Profitability Ratios
Gross Margin
87.2%
Operating Margin
-82.3%
Net Margin
-88.8%
ROE
-45.1%
ROA
-13.2%
FCF Margin
-83.2%
Balance Sheet & Liquidity
Current Ratio
10.20x
Quick Ratio
8.89x
Debt/Equity
2.01x
Debt/Assets
70.8%
Interest Coverage
-12.67x
Long-term Debt
58.5M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-13T08:13:06.378621 |
Data as of: 2026-03-31 |
Powered by Claude AI